Argenx
ARGX
#456
Rank
S$66.10 B
Marketcap
S$1,068
Share price
-0.85%
Change (1 day)
18.74%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total liabilities

Total liabilities on the balance sheet as of June 2025 : S$1.37 Billion

According to Argenx 's latest financial reports the company's total liabilities are S$1.37 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Argenx - Total liabilities on balance sheet (from 2019 to 2020)

Total liabilities by year

Year Total liabilities Change
2024-12-31S$0.95 B62.9%
2023-12-31S$0.58 B36.74%
2022-12-31S$0.42 B0.58%
2021-12-31S$0.42 B-46.65%
2020-12-31S$0.80 B38.21%
2019-12-31S$0.57 B709.03%
2018-12-31S$71.62 M43.21%
2017-12-31S$50.01 M-26.32%
2016-12-31S$67.88 M362.27%
2015-12-31S$14.68 M-10.84%
2014-12-31S$16.46 M106.06%
2013-12-31S$7.99 M-21.3%
2012-12-31S$10.15 M49.37%
2011-12-31S$6.79 M95.58%
2010-12-31S$3.47 M